Meeting
2016 ASCO Annual Meeting
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer (SCLC): GOIRC-AIFA FARM6PMFJM trial.
Authors
Marcello Tiseo
Azienda Ospedaliero-Universitaria of Parma, Parma, Italy
Marcello Tiseo , Luca Boni , Francesca Ambrosio , Andrea Camerini , Editta Baldini , Saverio Cinieri , Francesca Zanelli , Efisio Defraia , Matteo Brighenti , Lucio Crino , Claudio Dazzi , Carmelo Tibaldi , Gianni Michele Turolla , Vito D'Alessandro , Nicoletta Zilembo , Anna Rita Trolese , Francesco Grossi , Ferdinando Riccardi , Andrea Ardizzoni
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
2007-007949-13
Citation
J Clin Oncol 34, 2016 (suppl; abstr 8513)
DOI
10.1200/JCO.2016.34.15_suppl.8513
Abstract #
8513
Poster Bd #
141
Abstract Disclosures
Similar Posters
First Author: Ana Oaknin
Poster
2023 ASCO Annual Meeting
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R).
First Author: Patrick M. Forde
Poster
2023 ASCO Annual Meeting
Updated safety and efficacy results of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC) from a phase II trial.
First Author: Dawei Chen
Poster
2022 ASCO Annual Meeting
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
First Author: Jacob Sands